Leicester breakthrough in eye diseaseDecember 13, 2006Researchers at the University of Leicester have identified for the first time a gene which causes a distressing eye condition. Their discovery, as reported in the journal Nature Genetics, is expected to lead to better treatments for the condition. Nystagmus causes the eyes to move in an uncontrollable manner, so that people with the condition cannot keep their eyes still. Nystagmus can be congenital (occurs at birth or in early childhood) or acquired later in life due to neurological disease. Congenital nystagmus is frequently genetic. Treatment can be surgical, by correcting an abnormal head position (which occurs because the nystagmus is quietest in a certain direction of gaze) or by correcting a squint. The effects of Nystagmus can also be reduced by drugs. Recently, the University of Leicester Ophthalmology Group, headed by Professor Irene Gottlob, has shown that drug treatment is helpful in congenital nystagmus, as well as in the form that develops later. The frequency of nystagmus is unknown. However, over the last six years the Leicester Ophthalmology Group has counted all patients with the condition in the 'Leicestershire Nystagmus Survey', showing an occurrence of more than two in 1000 people. Professor Gottlob commented: "The discovery of this gene will make a genetic test for idiopathic X-linked nystagmus possible. So far it has not been understood what the causes of nystagmus are. The discovery of the gene will lead to greater understanding about the protein which is abnormal in nystagmus. "Our research also showed that the expression of the protein is changed in neuronal cells of the eye and in certain parts of the brain. Further research is now needed to understand what functional changes in the brain the gene mutations are causing. "This will be the first time the mechanisms of nystagmus have been understood, and we hope it will lead to better drug treatments. Understanding the mechanism of nystagmus will also improve our knowledge of the control in eye movements in general." Nystagmus, largely under-researched, is one of a significant number of interests within the Leicester Ophthalmology Group concerned with normal and abnormal eye movements. Researchers are looking into many aspects of nystagmus, including possible drug treatments, its epidemiology, impact on visual function, adaptation of the visual system to the constant eye movements, the causes of the condition and its genetic make-up. They are also investigating other eye movement problems, such as reading in schizophrenia and treatment for amblyopia (a lazy eye), including patching therapy with special reward incentives and the education of parents and teachers. University of Leicester |
|||||||||||||||||||||
| Related Eye Disease Current Events and Eye Disease News Articles Researchers find new way to attack inflammation in Graves' eye disease A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Cataract surgery helps AMD patients; steroid improves DME; online eye health forum This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit patients with age-related macular degeneration (AMD) at all stages of the disease, on a clinical trial showing that the steroid triamcinolone may be effective in advanced diabetic macular edema (DME) patients when standard treatment fails, and on the public's use of two Academy-sponsored online eye health forums. Experimental treatments restore partial vision to blind people Two experimental treatments, a retinal prosthesis and fetal tissue transplant, restored some vision to people with blinding eye diseases. The findings, presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health, may lead to new treatments for the blind. Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). Toronto researchers discover novel circulation in human eye, new glaucoma treatment target Researchers at the University of Toronto, St. Michael's Hospital and Sunnybrook Health Sciences Centre have discovered a previously unidentified form of circulation within the human eye which may provide important new insights into glaucoma, a leading cause of blindness. International conference on endothelin One of the most intriguing developments in recent medical science is the discovery of the human chemical endothelin (ET). JDRF-funded studies show regular CGM use increases diabetes control for all age groups The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors - six days per week or more - rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices - including experiencing fewer low blood sugar emergencies. Elevated arginase levels contribute to vascular eye disease such as diabetic retinopathy Elevated levels of the enzyme arginase contribute to vascular eye damage and Medical College of Georgia researchers say therapies to normalize its levels could halt progression of potentially blinding diseases such as diabetic retinopathy. Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases A new class of antibody drugs may provide a powerful new tool for the treatment of eye diseases in children, but specialists need to be alert for the possibility of serious side effects, according to an editorial in the August Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus), published by Elsevier. Natural Compound Stops Diabetic Retinopathy Researchers at the University of Oklahoma Health Sciences Center have found a way to use a natural compound to stop one of the leading causes of blindness in the United States. More Eye Disease Current Events and Eye Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||